StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.00 (-0.65%)

Close on Nov 17, 2026Market cap $257.81KP/E –Yield –

Virax Biolabs price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Virax Biolabs's price to sales ratio was 29.2× on Nov 11, 2026, against 276.1× a year earlier. Over the last 3 years it ranged from 16.1× to 445.5×, with a median of 130.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202629.2×−207.9
2025Dec 31, 2025237.2×+200.1
2024Dec 31, 202437.0×−228.1
2023Dec 29, 2023265.1×–

More Virax Biolabs figures

See a number that looks wrong?